Drug Trial Radar · NCT05828511
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
148
Actual
Start
Dec 19, 2023
Primary completion
Nov 2, 2035
Study completion Nov 2, 2035
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Apr 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM. This study consists of 2 phases: * In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2. * In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug. * In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM. The study is looking at several research questions, including: * What side effects may happen from taking linvoseltamab? * What the right dosing regimen is for linvoseltamab? * How many participants treated with linvoseltamab have improvement of their disease and for how long? * The effects of linvoseltamab study treatment before and after transplant * How much linvoseltamab is in the blood at different times? * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
Conditions
- Multiple Myeloma
Interventions
LinvoseltamabDrug
Linvoseltamab will be administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: End of the Observation period; up to day 28
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Post-Last Linvoseltamab Dose, up to 90 days
- Severity of TEAEsTime frame: Post-Last Linvoseltamab Dose, up to 90 days
- Incidence of Adverse Events of Special Interest (AESIs)Time frame: Post-Last Linvoseltamab Dose, up to 90 days
- Severity of AESIsTime frame: Post-Last Linvoseltamab Dose, up to 90 days
- Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteriaTime frame: Up to 5 years
- Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapyTime frame: Up to 5 years
- Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapyTime frame: Up to 5 years
- Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period IITime frame: Up to 5 years
- Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period IITime frame: Up to 5 years
Locations
32 sites in 3 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA)
Los Angeles, California
UC Irvine Health
Orange, California
Colorado Blood Cancer Institute/SCRI
Denver, Colorado
Norton Cancer Institute
Louisville, Kentucky
Karmanos Cancer Institute
Detroit, Michigan
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York
Perlmutter Cancer Center
New York, New York
Columbia University _ New York Presbyterian
New York, New York
Stony Brook University Hospital
Stony Brook, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University Health System (DUHS)
Durham, North Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
CHU De Lille
Lille, France
Centre Hospitalier Universitaire (CHU) Montpellier
Montpellier, France
Hopital Saint Louis
Paris, France
University Hospitals Pitie Salpetriere - Charles Foix
Paris, France
Hopital Prive d'Antony
Antony, Île-de-France Region, France
Hopital Necker
Paris, Île-de-France Region, France
Gustave Roussy
Villejuif, Île-de-France Region, France
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, Vienne, France
Hospital Clinic de Barcelona
Barcelona, Spain
Institut Catala dOncologia (ICO Hospitalet)
Barcelona, Spain
Universitary Hospital La Princesa
Madrid, Spain
Clinica Universidad de Navarra - Madrid
Madrid, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Universitario Quiron Salud Madrid
Pozuelo de Alarcón, Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital General Universitario Doctor Balmis Alicante
Alicante, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.